Could Ozempic Slow Aging? A New Clinical Trial Analysis Opens The Door

HIV Patients on Ozempic Were Aging Up to 4.9 Fewer Biological Years Per Year, Trial Analysis Finds

Millions of people already take semaglutide to lose weight or protect their hearts. A new clinical trial analysis suggests the drug may also be capable of slowing the rate at which the body biologically ages.

Blood samples taken from adults with HIV during a 32-week randomized, controlled trial showed measurably slower rates of biological aging in those who received the drug compared to those who got a placebo, and the effect held up across multiple independent tests. Published in Nature Communications, the analysis marks the first randomized trial evidence that semaglutide, the active ingredient in Ozempic and Wegovy, can measurably affect biological aging markers.

Biological age and chronological age are not the same thing. A person can be 50 years old by the calendar but have a body that functions more like a 60-year-old, or a 40-year-old. Scientists can now measure this gap using tools called epigenetic clocks, which read chemical changes on DNA that accumulate over time in patterns tied to health and disease risk. People with HIV tend to age faster biologically, even when their infection is well-managed, making them a practical population for testing whether a drug can push back against that accelerated aging process.

Semaglutide Trial Enrolled HIV Patients With Excess Abdominal Fat

This was not a study designed from scratch to test aging. It was a deeper look inside an already completed trial. The original study was a phase 2 randomized, double-blind, placebo-controlled trial designed to test whether semaglutide could reduce excess body fat in people with HIV-associated lipohypertrophy, a condition where abnormal fat accumulates around the abdomen and internal organs. Neither the participants nor the researchers knew who was receiving the real drug or the saline placebo.

A total of 108 adults were enrolled, 54 to semaglutide and 54 to placebo. Participants had to be at least 18, have a confirmed HIV diagnosis, be on stable HIV medication for at least 12 weeks, and have a body mass index of 25 or higher. People with diabetes or active heart disease were excluded. Semaglutide was injected once weekly, starting at a low dose and stepping up over eight weeks before continuing at full dose through week 32.

Of the 108 participants, 84 had blood samples available at both the start and end of the study, 45 in the semaglutide group and 39 in placebo. The average age was 49, and about 42 percent were women. Fifty-eight percent were Black, 38 percent were White, and 11 percent were Hispanic.

Semaglutide Users Were Aging up to 4.9 Fewer Biological Years Per Year

Researchers ran the blood samples through 17 different epigenetic clocks, essentially different scientific instruments for reading how fast a person’s biology appears to be aging. Across the more advanced clocks, semaglutide produced consistent, statistically significant reductions in biological aging rates compared to placebo. One measure called PhenoAge, which predicts risk of death and disease, showed the largest effect: participants on semaglutide were aging nearly 4.9 fewer biological years per calendar year compared to those on placebo. Another well-regarded measure called DunedinPACE showed that participants on semaglutide were aging approximately 9 percent more slowly than those on placebo.

Blood-Based Clocks Pointed to Changes Across Several Body Systems

Perhaps the most expansive part of the analysis involved 11 organ-specific aging clocks measurable from a single blood sample. These tools use patterns in blood to estimate aging signals linked to different body systems, including the brain, heart, liver, kidneys, and lungs. Semaglutide was associated with meaningful reductions in biological aging across seven of these system-specific measures, with the largest effects in clocks tracking inflammation, brain aging, and metabolic aging. Four other system clocks trended in the same direction but did not reach statistical significance, possibly because the sample was small. The researchers tested whether shifts in immune-cell types might explain the findings and found no significant differences between groups, though they note subtle effects cannot be fully ruled out.

Researchers Say Larger Trials Are Needed Before Broader Conclusions

This was an exploratory analysis added onto a trial with different primary goals, and that distinction matters. The sample was relatively small, the follow-up was only 32 weeks, and the population was specific: middle-aged adults with HIV and excess abdominal fat, without diabetes or heart disease. Whether these results would hold in HIV-negative people, in older adults, or over longer treatment periods remains an open question.

Epigenetic clocks are statistical predictors, not definitive proof that cells are biologically younger or that a person will live longer, and blood-based measurements cannot confirm what is actually happening inside specific organs. The paper is currently an unedited Article in Press, meaning it may still undergo final editing before final publication. Purpose-built trials in larger and more diverse populations are the necessary next step before semaglutide can seriously be considered a tool for slowing human aging more broadly.

---

Disclaimer: This article is based on a post hoc exploratory analysis published as an unedited Article. The findings have not been replicated in larger or more diverse populations and should not be interpreted as proof that semaglutide extends lifespan or slows aging in the general population.

---